Мероприятия

 

Эффективность разных методов лечения местного рецидива рака предстательной железы
Автор: А. Цой, Э. Ромазанов   

 

magazine-vrach-2013-11-009

Эффективность разных методов лечения местного рецидива рака предстательной железы

Анализируется эффективность предложенных методов лечения местного рецидива рака предстательной железы.
Efficiency of different treatments for locally recurrent prostate cancer
The paper analyzes the efficiency of proposed treatments for locally recurrent prostate cancer.
Литература:
1.Gallina A., Chun F., Suardi N. et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer // BJU Int. – 2008; 101 (12): 1513–8.
2. Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации // Экспер. и клин. урол. – 2011; 2 (3): 6–7.
3. Аполихин О.И., Сивков А.В., Бешлиев Д.А. и др. Анализ урологической заболеваемости в Российской Федерации в 2002–2009 годах по данным официальной статистики // Экспер. и клин. урол. – 2011; 1: 4–10.
4. Shariat S., Kattan M., Vickers A. et al. Critical review of prostate cancer predictive tools // Fut. Oncol. – 2009; 5 (10): 1555–84.
5. Liebross R., Pollack A., Lankford S. et al. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome // Cancer. – 1999; 85 (7): 1577–85.
6. Zalesky M., Urban M., Smerhovský Z. et al. Value of power Doppler sonography with 3D-reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer // Int. J. Urol. – 2008; 15 (1): 68–75.
7. Soylu F., Eggener S., Oto A. Local staging of prostate cancer with MRI // Diagn. Interv. Radiol. – 2012; 18 (4): 365–73.
8. Heuck A., Scheidler J., Sommer B. et al. MR imaging of prostate cancer // Radiologe. – 2003; 43 (6): 464–73.
9. Wang L., Zhang J., Schwartz L. et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI // AJR Am. J. Roentgenol. – 2007; 188 (1): 99–104.
10. Baccos A., Schiavina R., Zukerman Z. et al. Accuracy of endorectal Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced-MRI (DCE-MRI) in the preoperative local staging of prostate cancer // Urologia. – 2012; 79 (2): 116–22.
11. Isbarn H., Wanner M., Salomon G. et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era // BJU Int. – 2010; 106 (1): 37–43.
12. Roehl K., Han M., Ramos C. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3 478 consecutive patients: long-term results // J. Urol. – 2004; 172 (3): 910–4.
13. Porter C., Kodama K., Gibbons R. et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series // J. Urol. – 2006; 176 (2): 569–74.
14. Hull G., Rabbani F., Abbas F. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients // J. Urol. – 2002; 167 (2): 528–34.
15. Ward J., Slezak J., Blute M. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome // BJU Int. – 2005; 95 (6): 751–6.
16. Hsu C.-Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience // Eur. Urol. – 2007; 51 (1): 121–8.
17. Kupelian P., Kuban D., Thames H. et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995 // Int. J. Radiat. Oncol. Biol. Phys. – 2005; 61 (2): 415–9.
18. Peeters S., Heemsbergen W., Koper P. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy // J. Clin. Oncol. – 2006; 24 (13): 1990–6.
19. Grimm P., Blasko J., Sylvester J. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy // Int. J. Rad. Oncol. Biol. Phys. – 2001; 51 (1): 31–40.
20. Potters L., Klein E., Kattan M. et al. Kupelian. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation // Radiother. Oncol. – 2004; 71 (1): 29–33.
21. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer // J. Urol. – 2008; 179 (5): 20–4.
22. Stone N., Stock R., Unger P. Intermediate term biochemical-free progression and local control following 125-iodine brachytherapy for prostate cancer // J. Urol. – 2005; 173 (3): 803–7.
23. Zelefsky M., Kuban D., Levy L. et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation // Int. J. Rad. Oncol. Biol. Phys. – 2007; 67 (2): 327–33.
24. Lawton C., Hunt D., Lee W. et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05) // Int. J. Rad. Oncol. Biol. Phys. – 2011; 81 (1): 1–7.
25. Aus G. Current status of HIFU and cryotherapy in prostate cancer. A review // Eur. Urol. – 2006; 50 (5): 927–34.
26. Long J., Bahn D., Lee F. et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate // Urology. – 2001; 57 (3): 518–23.
27. Bhatta-Dhar N., Reuther A., Zippe C. et al. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer // Urology. – 2004; 63 (3): 528–31.
28. Kupelian P., Potters L., Khuntia D. et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. – 2004; 58 (1): 25–33.
29. Boorjian S., Karnes R., Rangel L. et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy // J. Urol. – 2008; 179 (4): 1354–60.
30. Nguyen P., Chen M.-H., Catalona W. et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: implications for management // Cancer. – 2008; 113 (11): 3146–52.
31. Weight C., Reuther A., Gunn P. et al. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer // Urology. – 2008; 71 (1): 141–5.
32. Kane C., Im R., Amling C. et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database // Urology. – 2010; 76 (3): 695–700.
33. Menon M., Bhandari M., Gupta N. et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up // Eur. Urol. – 2010; 58 (6): 838–46.
34. Bittner N., Merrick G., Galbreath R. et al. Primary causes of death after permanent prostate brachytherapy // Int. J. Rad. Oncol. Biol. Phys. – 2008; 72 (2): 433–40.
35. Hinnen K., Battermann J., van Roermund J. et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy // Int. J. Rad. Oncol. Biol. Phys. – 2010; 76 (5): 1433–8.
36. Coen J., Zietman A., Rossi C. et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis // Int. J. Rad. Oncol. Biol. Phys. – 2012; 82 (1): 25–31.
37. Bahn D., Lee F., Badalament R. et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer // Urology. – 2002; 60 (2): 3–11.
38. Thüroff S., Chaussy C. Evolution and outcomes of 3 MHz High intensity focused ultrasound therapy for localized prostate cancer over 15 years // J. Urol. – 2013 Feb. (online).
39. Asimakopoulos A., Miano R., Virgili G. et al. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study // Urol. Oncol. – 2012; 30 (5): 577–83.
40. Touma N., Izawa J., Chin J. Current status of local salvage therapies following radiation failure for prostate cancer // J. Urol. – 2005; 173 (2): 373–9.
41. Borland R., Walsh P. The management of rectal injury during radical retropubic prostatectomy // J. Urol. – 1992; 147 (3): 905–7.
42. Schmitges J., Trinh Q.-D., Sun M. et al. Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy // Urology. – 2012; 79 (4): 796–803.
43. Chade D., Shariat S., Cronin A. et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration // Eur. Urol. – 2011; 60 (2): 205–10.
44. Cheng L., Sebo T., Slezak J. et al. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy // Cancer. – 1998; 83 (10): 2164–71.
45. Kaffenberger S., Keegan K., Bansal N. et al. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience // J. Urol. – 2013; 189 (2): 507–13.
46. Pisters L., von Eschenbach A., Scott S. et al. The efficacy and complications of salvage cryotherapy of the prostate // J. Urol. – 1997; 157 (3): 921–5.
47. Cespedes R., Pisters L., von Eschenbach A. et al. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients // J. Urol. – 1997; 157 (1): 237–40.
48. de la Taille A., Hayek O., Benson M. et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience // Urology. – 2000; 55 (1): 79–84.
49. Spiess P., Levy D., Pisters L. et al. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry // W. J. Urol. – 2012; 26 (5): 498.
50. Grado G., Collins J., Kriegshauser J. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure // Urology. – 1999; 53 (1): 2–10.
51. Beyer D. Permanent brachytherapy as salvage treatment for recurrent prostate cancer // Urology. – 1999; 54 (5): 880–3.
52. Moman M., van der Poel H., Battermann J. et al. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy // Brachytherapy. – 2010; 9 (2): 119–25.
53. Chen C., Weinberg V., Shinohara K. et al. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes // Int. J. Rad. Oncol. Biol. Phys. – 2013; 86 (2): 324–9.
54. Shimbo M., Inoue K., Koike Y. et al. Salvage I Seed Implantation for Prostate Cancer with Postradiation Local Recurrence // Urol. Int. – 2013; 90 (3): 294–300.
55. Murat F.-J., Poissonnier L., Rabilloud M. et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer // Eur. Urol. – 2009; 55 (3): 640–7.
56. Uchida T., Shoji S., Nakano M. et al. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy // BJU Int. – 2011; 107 (3): 378–82.
57. Ahmed H., Cathcart P., Chalasani V. et al. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy // Cancer. – 2012; 118 (12): 3071–8.
58. Crouzet S., Murat F.-J., Pommier P. et al. Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes // Radiother. Oncol. – 2012; 105 (2): 198–202.
59. Berge V., Baco E., Karlsen S. A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results // Scand. J. Urol. Nephrol. – 2010; 44 (4): 223–7.

 

 

 
Рассылка
Важно

→ Фармакопейные статьи


→ Медицинские архивы на службе современного врача


→ Перечень медицинских технологий

ЭКД архив

 

Баннер
Баннер
Баннер
Информационные партнеры:
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер